Corsmed, a pioneer in Medical Imaging technology, has secured $3.5 Million in Seed funding, thus taking the total funding of the entity to $10 Million. The recent funds raised will assist Corsmed advance its development and the clinical application of new superior MRI scan technology.
For example, MRI is known to provide explicit health information pertaining to the human body, but it has limitations in that it is quite expensive and time-consuming.
Corsmed is revolutionizing this landscape by employing the (DGTL Twin) digital twin to analyze and lessen MRI scanning time from 45 min to 2-3 min. The advancement of this innovation will facilitate the prevention of health care by reducing both the time and the cost of advanced imaging.
AI-Facilitated Software for Enhanced Efficiency in Scans
Corsmed’s new software boosted up with AI accelerates shows a great impartment over the other existing solutions. While today, current AI systems can shorten MRI scans by 20-40%, Corsmed’s software can make high-resolution 3D brain scans in 3 minutes, which is 10 times faster.
Furthermore, unlike other qualitative MRIs where patients are interpreted qualitatively, Corsmed’s software produces quantitative scan images with actual values to ensure comparability across patients and anytime.
Aiming to Democratize MRI Access
Corsmed’s CEO, Erik Jacobsson, added that the company’s long-term strategic goal was to make MRI scans affordable for everyone and save millions of lives every year from diseases that could have been detected early.
They imagine a future where simple whole-body quantitative scans could help identify diseases such as cancer at their earliest curable stages, reducing deaths substantially.
Industry Support and Recognition
MRI simulator by Corsmed is already being employed in such renowned facilities as The Christie NHS Foundation Trust and University College London Hospitals NHS Foundation Trust to train medical personnel and save money.
The firm also intends to seek FDA certification and engage in HIPAA compliance processes as it continues to offer its technology for clinical application.
